Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02660645 · ClinicalTrials.gov registry record
Blue Light Cystoscopy With Cysview® Registry
A clinical trial of Bladder Cancer, sponsored by Photocure.
- Recruiting
- Registry status
- 4,400
- Enrollment target
- 20
- Study locations
NCT02660645 is a study of Bladder Cancer that is actively recruiting participants, run by Photocure. The registered enrollment target is 4,400 participants, below the 12,729-participant average among 175 other Bladder Cancer trials with a reported enrollment target (65% lower). The trial reports 20 study locations across 14 states.
The verdict
NCT02660645, a study of Bladder Cancer, is actively recruiting participants, sponsored by Photocure.
- RECRUITING
- Registry status
- 4,400 participants
- Enrollment target
- 20
- Study locations
Study Summary
Registry study to gather more information on the current use of Blue Light Cystoscopy with Cysview (BLCC) in urologists' practices.
Conditions Studied
Interventions
- DEVICE Karl Storz D-Light C Photodynamic Diagnostic (PDD) system
- DRUG Hexaminolevulinate hydrochloride (HCL)
Study Locations (20)
California
- USC/Norris Comprehensive Cancer Center - Los Angeles
- University of California Los Angeles - Los Angeles
- VA Palo Alto Health Care System - Palo Alto
- University of California, San Francisco - San Francisco
Illinois
- Northwestern University - Chicago
- Northshore University Health System - Evanston
New York
- NYU Langone's Perlmutter Cancer Center - New York
- Stony Brook Urology - Stony Brook
Ohio
- Ohio State University Wexner Medical Center - Columbus
- Ohio State University - Columbus
Alabama
- The University of Alabama at Birmingham - Birmingham
Arizona
- Mayo Clinic - Phoenix
District of Columbia
- Sibley Memorial Hospital - Washington D.C.
Georgia
- Emory University School of Medicine - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,400 participants |
| Start Date | 2014-04 |
| Est. Completion | 2028-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02660645
The ClinicalTrials.gov registry entry for NCT02660645 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 4,400 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 12,729-participant average among 175 other Bladder Cancer trials with a reported enrollment target (65% lower). The listed sponsor is Photocure, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Bladder Cancer appearing as the primary indexed condition, and to 2 interventions - of which Karl Storz D-Light C Photodynamic Diagnostic (PDD) system is the first listed.
NCT02660645 reports 20 study locations spanning 14 distinct geographic areas - top geographies include California, Illinois, New York.
Frequently Asked Questions
What is clinical trial NCT02660645 about?
NCT02660645 is a clinical study titled "Blue Light Cystoscopy With Cysview® Registry". Registry study to gather more information on the current use of Blue Light Cystoscopy with Cysview (BLCC) in urologists' practices.
What is the current status of trial NCT02660645?
This trial is currently recruiting. The enrollment target is 4,400 participants. The study started on 2014-04. Estimated completion is 2028-12.
What conditions does trial NCT02660645 study?
This clinical trial studies the following conditions: Bladder Cancer.
What interventions are being tested in trial NCT02660645?
The interventions under investigation include: Karl Storz D-Light C Photodynamic Diagnostic (PDD) system (DEVICE), Hexaminolevulinate hydrochloride (HCL) (DRUG).
Who is sponsoring clinical trial NCT02660645?
This trial is sponsored by Photocure, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02660645 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, District of Columbia, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bladder Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
RECRUITING · Phase 1
-
Home Intravenous Fluid Infusion After Undergoing Radical Cystectomy
RECRUITING · NA
-
KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)
RECRUITING · Phase 1
-
CONFIRM: Magnetic Resonance Guided Radiation Therapy
RECRUITING · NA
-
Intravesical Treatment of Bladder Cancer at Home, Multi-modal Treatment Support
RECRUITING · NA
-
Improving Care for Rural Patients With Solid Tumors
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.